NTRK1 and malignant colon neoplasm: Then, two clinically used anti-colon cancer drugs irinotecan (a DNA topoisomerase inhibitor) and regorafenib (a multi-targeted receptor tyrosine kinase inhibitor) were separately added into the organoids with various concentrations.